Stemness Characteristics of Fibrolamellar Hepatocellular Carcinoma: Immunohistochemical Analysis with Comparisons to Conventional Hepatocellular Carcinoma

被引:1
|
作者
Zenali, Maryam J. [1 ,2 ]
Tan, Dongfeng [3 ]
Li, Wei [1 ,2 ]
Dhingra, Sadhna [1 ,2 ]
Brown, Robert E. [1 ,2 ]
机构
[1] Univ Texas Hlth Sci Ctr Houston, Dept Pathol, Houston, TX 77030 USA
[2] Univ Texas Hlth Sci Ctr Houston, Dept Lab Med, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源
关键词
fibrolamellar hepatocellular carcinoma; cancer stem cells; CD133; CD44; PPAR-gamma; beta-catenin; Ki-67; Skp2; CELLS; CANCER; EXPRESSION; LIVER; THERAPY; CD133; PROLIFERATION; RESISTANCE; CAPACITY; SURVIVAL;
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The involvement of cancer stem cells (CSC) in tumorigenesis has been studied in several malignancies, but their presence in fibrolamellar hepatocellular carcinoma (FLHCC) has not previously been evaluated. General characteristics of "stemness" include the expression of putative stem cell antigens, reduced cell cycle progression, and limited functional differentiation or dedifferentiation under the influence of the microenvironment. Immunohistochemical probes applied to 8 archival cases of FLHCC vis-a-vis contiguous non-neoplastic parenchyma, which was present in 5 cases, revealed such stemness characteristics by showing: (a) stem cell antigens, with moderate to intense expression of CD133 in the cytoplasm (6 of 8 FLHCC cases and comprising >40% of the tumoral areas) and of CD44 on the plasmalemmal aspect (7 of 8 FLHCC cases and comprising 50 to 95% of the tumor cells), vs foci of such overexpressions in only 1 of 5 of the contiguous liver parenchyma (p = 0.053 and p = 0.015, respectively); (b) limited G1 to S phase progression (<1% of tumor cells with nuclear S phase kinase-associated protein [Skp]2 expression); and (c) dedifferentiation or reduced functional differentiation in the form of minimal to absent expression of a differentiation-associated marker, peroxisomal proliferator-activator receptor (PPAR)-gamma in tumoral nuclei and loss of plasmalemmal expression of beta-catenin in 6 of 8 FLHCC cases vs expression of these proteins in the non-neoplastic, differentiated hepatocytes in 5 of 5 and 4 of 5 cases, respectively, in contiguous liver parenchyma (p <0.01 and p = 0.053, respectively). In contrast, only 1 of 11 cases of well-differentiated, conventional hepatocellular carcinoma (HCC) showed mild to moderate expression of CD133 in the cytoplasm, but with the majority (8 of 11) showing occasional nuclear expression. Similarly, only 3 of 11 cases of conventional HCC expressed plasmalemmal CD44. Notably, 11 of 11 cases of conventional HCC expressed beta-catenin on the plasmalemmal aspect of the tumor cells, and 3 of 11 showed nuclear translocation. These findings in conventional HCC were significantly different from those in FLHCC (p = 0.003, 0.009, and 0.0005, respectively). This study provides evidence of stemness in FLHCC and discusses the implications of stemness in the histogenesis of FLHCC vs conventional, well-differentiated HCC.
引用
收藏
页码:126 / 134
页数:9
相关论文
共 50 条
  • [21] FIBROLAMELLAR HEPATOCELLULAR-CARCINOMA
    KWEE, HG
    AMERICAN FAMILY PHYSICIAN, 1989, 40 (02) : 175 - 177
  • [22] FIBROLAMELLAR HEPATOCELLULAR-CARCINOMA
    RUFFIN, MT
    ANNALS OF INTERNAL MEDICINE, 1988, 109 (07) : 596 - 597
  • [23] Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma
    Suguru Yamashita
    Jean-Nicolas Vauthey
    Ahmed O. Kaseb
    Thomas A. Aloia
    Claudius Conrad
    Manal M. Hassan
    Guillaume Passot
    Kanwal P. Raghav
    Mohamed A. Shama
    Yun Shin Chun
    Journal of Gastrointestinal Surgery, 2016, 20 : 1725 - 1731
  • [24] Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma
    Yamashita, Suguru
    Vauthey, Jean-Nicolas
    Kaseb, Ahmed O.
    Aloia, Thomas A.
    Conrad, Claudius
    Hassan, Manal M.
    Passot, Guillaume
    Raghav, Kanwal P.
    Shama, Mohamed A.
    Chun, Yun Shin
    JOURNAL OF GASTROINTESTINAL SURGERY, 2016, 20 (10) : 1725 - 1731
  • [25] Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma
    Riggle, Kevin M.
    Turnham, Rigney
    Scott, John D.
    Yeung, Raymond S.
    Riehle, Kimberly J.
    PEDIATRIC BLOOD & CANCER, 2016, 63 (07) : 1163 - 1167
  • [26] Adult-type hepatocellular carcinoma in the center of a fibrolamellar hepatocellular carcinoma
    Seitz, G
    Zimmermann, A
    Friess, H
    Büchler, MW
    HUMAN PATHOLOGY, 2002, 33 (07) : 765 - 769
  • [27] Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis
    Kakar, S
    Burgart, LJ
    Batts, KP
    Garcia, J
    Jain, D
    Ferrell, LD
    MODERN PATHOLOGY, 2005, 18 (11) : 1417 - 1423
  • [28] A PLEOMORPHIC HEPATOCELLULAR-CARCINOMA WITH BIOCHEMICAL FEATURES OF FIBROLAMELLAR HEPATOCELLULAR-CARCINOMA
    BUAMAH, PK
    MCARDLE, P
    BENNETT, M
    JAMES, OFW
    LENDRUM, R
    JOURNAL OF SURGICAL ONCOLOGY, 1986, 32 (02) : 93 - 95
  • [29] Outcome of patients with fibrolamellar hepatocellular carcinoma
    Stipa, F
    Yoon, SS
    Liau, KH
    Fong, YM
    Jarnagin, WR
    D'Angelica, M
    Abou-Alfa, G
    Blumgart, LH
    DeMatteo, RP
    CANCER, 2006, 106 (06) : 1331 - 1338
  • [30] Transcriptomic characterization of fibrolamellar hepatocellular carcinoma
    Simon, Elana P.
    Freije, Catherine A.
    Farber, Benjamin A.
    Lalazar, Gadi
    Darcy, David G.
    Honeyman, Joshua N.
    Chiaroni-Clarke, Rachel
    Dill, Brian D.
    Molina, Henrik
    Bhanot, Umesh K.
    La Quaglia, Michael P.
    Rosenberg, Brad R.
    Simon, Sanford M.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (44) : E5916 - E5925